Neuron– tag –
-
Parkinson’s Regenerative Medicine Milestone: iPSC-Derived Dopamine Precursors Safely Transplanted in First-in-Human Trial
Parkinson's NSW Sweden Overview A pivotal clinical trial led by Lund University has confirmed the safety and feasibility of transplanting iPSC-derived dopamine precursor cells into Parkinson's disease patients. Published in Nature Medici... -
Next-Gen Brain Organoids Reveal How APOE4 Astrocytes Drive Alpha-Synuclein Pathology, Unlocking New Therapeutic Targets
ALZFORUM USA Overview A novel mechanism by which APOE4, a major Alzheimer's risk gene, exacerbates neuropathology has been published in Cell Stem Cell, leveraging a newly developed human brain organoid model termed 'miBrains.' This six-c... -
USC Initiates Phase 1 REPLACE™ Clinical Trial for Parkinson’s with Autologous iPSC-Derived Dopaminergic Neurons (RNDP-001), Aiming to Restore Motor Function
Dr. Marie Laguna's Blog USA Overview Keck Medicine of USC commenced a Phase 1 REPLACE™ clinical trial in 2026 for Parkinson's disease, utilizing autologous iPSC-derived dopaminergic neural cells (RNDP-001). This innovative therapy aims t... -
Commercial-Scale iPSC Cell Therapy Production Gains Traction with US Clinical Trial Progress and Master Cell Bank Establishment
The Medicine Maker UK Overview Manufacturing challenges for commercial-scale iPSC cell therapies are being overcome, with multiple iPSC clinical trials progressing in the U.S. for indications like Type 1 Diabetes, Parkinson's disease, an... -
Xellsmart Secures FDA Fast Track Designation for Parkinson’s iPSC-Derived Cell Therapy, Accelerating CNS Pipeline
Longevity.Technology UK Overview Xellsmart announced its allogeneic, off-the-shelf iPSC-derived cell therapy for Parkinson's disease has received FDA Fast Track designation, expected to accelerate its development program. Specializing in... -
BlueRock Therapeutics Advances iPSC-Derived Dopamine Neuron Therapy bemdaneprocel to Phase 3 for Parkinson’s, Demonstrating Significant Motor Improvement in Early Data
RegenMed Review USA Overview BlueRock Therapeutics' iPSC-derived dopamine neuron therapy, bemdaneprocel, is progressing to a Phase 3 trial (exPDite-2) for Parkinson's disease. Earlier 36-month Phase 1 data showed clinically meaningful im... -
Chronic Exposure to Chlorate at Regulatory Safety Limits Induces p21/p16-Mediated Neuronal Senescence and Parkinsonian Decline in iPSC-Derived Neurons
PubMed International Overview This research reports that chronic exposure to chlorate at concentrations within regulatory safety limits accelerates neuronal senescence in human iPSC-derived dopaminergic neurons, leading to Parkinsonian-l... -
China’s Xellsmart Secures FDA Fast Track for Off-the-Shelf Stem Cell Therapy XS411 in Parkinson’s Disease, Demonstrating Efficacy in Early-Stage Patients in Chinese Phase 1/2 Trial
Endpoints News China Overview China-based Xellsmart's off-the-shelf stem cell therapy, XS411, for Parkinson's disease, has received FDA Fast Track designation. XS411 aims to replace lost dopamine-producing neurons and restore neurologica... -
Aspen Neuroscience’s Personalized Cell Therapy Sasineprocel (ANPD001) Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Parkinson’s Disease
Longevity.Technology USA Overview Aspen Neuroscience announced that sasineprocel (ANPD001), its personalized cell therapy for Parkinson's disease, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA... -
Aspen Neuroscience’s ANPD001 Cell Therapy for Parkinson’s Disease Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation, Signaling Accelerated Development
RegMedNet USA Overview A RegMedNet report indicates that Aspen Neuroscience's ANPD001 cell therapy for Parkinson's disease has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA, based on preliminary Pha...
